NO20041850L - Fremgangsmate for dannelse av profenkrystaller - Google Patents

Fremgangsmate for dannelse av profenkrystaller

Info

Publication number
NO20041850L
NO20041850L NO20041850A NO20041850A NO20041850L NO 20041850 L NO20041850 L NO 20041850L NO 20041850 A NO20041850 A NO 20041850A NO 20041850 A NO20041850 A NO 20041850A NO 20041850 L NO20041850 L NO 20041850L
Authority
NO
Norway
Prior art keywords
prophene
crystals
forming
prophene crystals
forming prophene
Prior art date
Application number
NO20041850A
Other languages
English (en)
Norwegian (no)
Inventor
Bernd Willi Werner Mueller
Heinz Einig
Norbert Rasenack
Kat Friese
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of NO20041850L publication Critical patent/NO20041850L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
NO20041850A 2001-11-06 2004-05-05 Fremgangsmate for dannelse av profenkrystaller NO20041850L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10153934A DE10153934A1 (de) 2001-11-06 2001-11-06 Verfahren zur Kristallisation von Profenen
PCT/EP2002/011999 WO2003039513A1 (de) 2001-11-06 2002-10-25 Verfahren zur bildung von profenkristallen

Publications (1)

Publication Number Publication Date
NO20041850L true NO20041850L (no) 2004-05-05

Family

ID=7704443

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041850A NO20041850L (no) 2001-11-06 2004-05-05 Fremgangsmate for dannelse av profenkrystaller

Country Status (14)

Country Link
US (1) US20050003000A1 (de)
EP (1) EP1443906A1 (de)
JP (1) JP2005512994A (de)
KR (1) KR20050039732A (de)
CN (1) CN1585630A (de)
BR (1) BR0213878A (de)
CA (1) CA2464756A1 (de)
DE (1) DE10153934A1 (de)
HU (1) HUP0402006A2 (de)
IL (1) IL161406A0 (de)
MX (1) MXPA04004236A (de)
NO (1) NO20041850L (de)
RU (1) RU2004117167A (de)
WO (1) WO2003039513A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005037630A1 (de) 2005-08-09 2007-02-15 Glatt Gmbh Verfahren zur Herstellung von Teilchen aus pharmazeutischen Substanzen, Teilchen aus pharmazeutischen Substanzen sowie deren Verwendung
CZ297830B6 (cs) * 2005-08-30 2007-04-11 I.Q.A., A. S. Zpusob výroby jemne krystalické smesi obsahující nesteroidní protizánetlivé lécivo, jemne krystalická smes pripravitelná tímto zpusobem a pevný farmaceutický prostredek tuto smes obsahující
AU2007275360B2 (en) 2006-07-18 2013-05-16 Horizon Medicines Llc Methods and medicaments for administration of ibuprofen
US9622966B2 (en) * 2007-07-06 2017-04-18 Basf Corporation Gastroretentive composition on the basis of a water-soluble reaction product from a vinyl group-containing precursor
US8216495B2 (en) * 2008-03-25 2012-07-10 Formac Pharmaceuticals N.V. Preparation method for solid dispersions
US20110301116A1 (en) * 2008-12-04 2011-12-08 The University Of Tokyo Nsaids-induced gastrointestinal mucosal disorder alleviator and manufacturing method thereof
JPWO2011010456A1 (ja) * 2009-07-24 2012-12-27 株式会社ネクスト21 NSAIDs含有外用剤及び当該外用剤の製造方法
JP5750856B2 (ja) * 2010-10-04 2015-07-22 ライオン株式会社 固形医薬組成物及び医薬製剤
US9248139B2 (en) * 2011-12-21 2016-02-02 Bristol-Myers Squibb Company Co-processing method and formulations for HIV attachment inhibitor prodrug compound and excipients
US10335371B2 (en) 2015-02-17 2019-07-02 Universiteit Gent Solid pharmaceutical dosage form suitable for use as drinking water medication
CN106397181B (zh) * 2016-09-08 2019-01-01 山东理工大学 一种通过添加十二烷基硫酸钠自水溶液中制备长针状布洛芬晶体的方法
CN106518655B (zh) * 2016-09-08 2019-01-04 山东理工大学 一种通过添加晶形控制剂自水溶液中制备片状布洛芬晶体的方法
CN110627629A (zh) * 2019-10-15 2019-12-31 山东新华制药股份有限公司 一种多级连续反应结晶生产布洛芬的方法
JP2023084097A (ja) * 2021-12-06 2023-06-16 花王株式会社 芳香族ヒドロキシカルボン酸結晶の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4476248A (en) * 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen
US5141961A (en) * 1991-06-27 1992-08-25 Richrdson-Vicks Inc. Process for solubilizing difficulty soluble pharmaceutical actives
GB9119052D0 (en) * 1991-09-06 1991-10-23 Boots Co Plc Pharmaceutical compositions
JP3390477B2 (ja) * 1993-01-25 2003-03-24 生化学工業株式会社 薬剤組成物及びその製造法
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen

Also Published As

Publication number Publication date
US20050003000A1 (en) 2005-01-06
HUP0402006A2 (hu) 2005-01-28
KR20050039732A (ko) 2005-04-29
MXPA04004236A (es) 2004-07-08
RU2004117167A (ru) 2005-04-10
JP2005512994A (ja) 2005-05-12
IL161406A0 (en) 2004-09-27
CN1585630A (zh) 2005-02-23
DE10153934A1 (de) 2003-05-22
EP1443906A1 (de) 2004-08-11
BR0213878A (pt) 2004-08-31
CA2464756A1 (en) 2003-05-15
WO2003039513A1 (de) 2003-05-15

Similar Documents

Publication Publication Date Title
NO20034969D0 (no) Fremgangsmåte for fremstilling av olefiner
DK1293507T3 (da) Fremgangsmåde til fremstilling af krystaller
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
NO20033902D0 (no) Fremgangsmåte for fremstilling av mellomdestillater
DE60211785D1 (de) Bilderzeugungsverfahren
NO20030012L (no) Fremgangsmåte for fremstilling av substituerte oktanoylamider
NO20052568D0 (no) Fremgangsmate for fremstilling av makrolidforbindelse
NO20033887D0 (no) Fremgangsmåte for fremstilling av stöpestykker
NO20040027L (no) Fremgangsmate for fremstillingen av escitalopram
DE60235767D1 (de) Sublimationsmuster-giessverfahren
NO20030163D0 (no) Fremgangsmåte for fremstilling av olefiner
NO20040278L (no) Fremgangsmate for fremstilling av perindopril
NO20041850L (no) Fremgangsmate for dannelse av profenkrystaller
NO20041182L (no) Fremgangsmate for fremstilling av silisium
NO20044814L (no) Fremgangsmate for fremstilling av combretastaniner
DE60233109D1 (de) Radidentifikator- ortungsverfahren
DE60130137D1 (de) Kristallisationsverfahren
NO20035586D0 (no) Fremgangsmåte for fremstilling av cykloheksanol-derivater
NO20041224L (no) Fremgangsmate for fremstilling av hydrokarboner
NO20001134L (no) FremgangsmÕte for fremstilling av VCM
DE60204089D1 (de) Bilderzeugungsverfahren
NO20023087D0 (no) Fremgangsmåte for fremstilling av kvartsdigler
FI20010472A0 (fi) Menetelmä alfa-pineenin hydraamiseksi
NO20030515D0 (no) Fremgangsmåte for fremstilling av dinapsolin
NO20014077L (no) Fremgangsmåte for krystallisering av N-(4-trifluormetylfenyl)- 5-metyl-isoksazol-4-karboksamid

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application